报告背景:今年以来中国创新药出海授权从数量和金额均出现重要突破,跨国药企深化与中国创新药企的战略合作乃大势所趋,此举将开创互利共赢的新局面。后续出海浪潮趋势如何演绎,已成为市场高度瞩目的焦点。报告亮点:我们相信,本篇报告无论是对于产业界还是投资界,都有重要的参考价值。因为我们全面深入剖析了跨国药企(MNC)的在研管线、战略重心及核心诉求,预测其未来BD可能的重要方向;全面评估了三大重要疾病领域的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.